Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement

Inclusion Criteria: * Male or female, age ≥ 18 years; * Planned total knee replacement surgery; * Signed informed consent form; * Willing to comply with the protocol; * Willing to use adequate contraception during the trial. Exclusion Criteria: * Surgery for acute fracture 4 weeks before screening; history of septic inflammation in the joint; prosthesis revision or one leg missing * History of venous thrombosis of any location or PE * History of heparin induced thrombocytopenia or other thrombocytopathy; hemorrhagic diathesis * History of evident coagulopathy or in a relative * Congenital thrombophilia * Bleeding within 6 months of screening; increased risk of bleeding * BMI less than 18,5 or more than 40 kg/m2 * Systolic BP \> 180 mmHg and/or diastolic BP \> 110 mmHg registered twice within 15-30 minutes * Hb ≤ 10.5 g/dL in female or ≤ 11.5 g/dL in male * Platelets \< 100 000/mm3 * Clinical significant abnormalities of APTT and/or INR * GFR \< 30 ml/min/1.73 m2 * ALT or AST ≥ 2 x ULN or total bilirubin ≥1,5 x ULN